Eating disorders are complex, chronic disorders that are difficult to treat. In addition, the 2 primary eating disorders, anorexia nervosa and bulimia nervosa, may have acute, life-threatening consequences. Medication trials for eating disorders have been hampered by high dropout rates, high placebo response, short trial duration, insufficient doses, and difficult outcome measures. Only 1 medication has been FDA approved for any eating disorder to date, and that is for fluoxetine in the treatment of bulimia. Clearly, new large-scale, independent studies using novel agents, and studying the use of medications for both short- and long-term outcomes, are needed.
HoekHWvan HoekenD. Review of the prevalence and incidence of eating disorders. Int J Eat Disord. 2003;34:383-339.
2.
WaltersEEKendlerKS. Anorexia nervosa and anorexic-like syndromes in a population-based female twin sample. Am J Psychiatry. 1995;152:64-71.
3.
GarfinkelPELinEGoeringP. Bulimia nervosa in a Canadian community sample: prevalence and comparison of subgroups. Am J Psychiatry. 1995;152:1052-1058.
4.
Reichborn-KjennerudTBulikCMSullivanP. Psychiatric and medical symptoms in binge eating in the absence of compensatory behaviors. Obes Res. 2004;12:1445-1454.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, DC: American Psychiatric Association; 2000.
7.
GoldenNHKatzmanDKKreipeRE. Eating disorders in adolescents: position paper of the Society for Adolescent Medicine. J Adolesc Health. 2003;33:496-503.
8.
KatzmanDKZipurskyRB. Adolescents with anorexia nervosa: the impact of the disorder on bones and brains. Ann N Y Acad Sci. 1997;817:127-137.
9.
WilfleyDEBishopMEWilsonGTAgrasWS. Classification of eating disorders: toward DSM-V. Int J Eat Disord. 2007;40(Suppl):S123-S129.
10.
SullivanP. Course and outcome of anorexia nervosa and bulimia nervosa. In: FairburnCGBrownellKD, eds. Eating Disorders and Obesity. 2nd ed.New York, NY: Guilford Press; 2002:226-232.
11.
SullivanPF. Mortality in anorexia nervosa. Am J Psychiatry. 1995;152:1073-1074.
12.
CrookMAHallyVPanteliJV. The importance of the refeeding syndrome. Nutrition. 2001;17:632-637.
13.
BrooksMJMelnikG. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Pharmacotherapy. 1995;15:713-726.
14.
KatzmanDK. Medical complications in adolescents with anorexia nervosa: a review of the literature. Int J Eat Disord. 2005;37:S52-S59.
15.
StroberMFreemanRLampertC. Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. Am J Psychiatry. 2000;157:393-401.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed.Washington, DC: American Psychiatric Association; 1980.
18.
VandereyckenW. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144:288-292.
19.
BiedermanJHerzogDBRivinusTM. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1985;5:10-16.
20.
HalmiKAEckertELaDuTJCohenJ. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986;43:177-181.
21.
BirminghamCLGoldnerEMBakanR. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord. 1994;15:251-255.
22.
BrambillaFDraisciAPeironeA. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders II. Anorexia nervosa-binge-eating/purging type. Neuropsychopharmacology. 1995;32:64-67.
23.
KlibanskiABillerBMSchoenfeldDA. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab. 1995;80:898-904.
24.
SzmuklerGIYungGPMillerG. A controlled trial of cisapride in anorexia nervosa. Int J Eat Disord. 1995;17:347-357.
25.
AttiaEHaimanCWalshBT. Does fluoxetine augment the inpatient treatment of anorexia nervosa?Am J Psychiatry. 1998;155:548-551.
26.
RiccaVMannucciEPaionniA. Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eat Weight Disord. 1999;4:10-14.
27.
HillKBucuvalasJMcClainC. Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J Child Adolesc Psychopharmacol. 2000;10:3-8.
28.
KayeWHNagataTWeltzinTE. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry. 2001;49:644-652.
29.
RuggieroGMLainiVMauriMC. A single blind comparison of amisulipride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:1049-1059.
30.
FassinoSLeombruniPDagaG. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol. 2002;12:453-459.
31.
BarbarichNCMcConahaCWHalmiKA. Use of nutritional supplements to increase the efficacy of fluoxetine in he treatment of anorexia nervosa. Int J Eat Disord. 2004;35:10-15.
32.
MillerKKGriecoKAKlibanskiA. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab. 2005;90:1428-1433.
33.
MondratyNBirminghamCLTouyzS. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry. 2005;13:72-75.
34.
WalshBTKaplanASAttiaE. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006;295:2605-2612.
35.
BrambillaFGarciaCSFassinoS. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22:197-204.
36.
BrambillaFMonteleoneMMajM. Olanzapine-induced weight gain in anorexia nervosa; involvement of leptin and ghrelin secretion. Psychoneuroendocrinology. 2007;32:402-406.
37.
AlexanderW. Prozac wins new indication for bulimia nervosa. Drug Topics. 1997;141:6.
38.
CrowSJMitchellJRoerigJD. What potential role is there for medication treatment in anorexia nervosa. Int J Eat Disord. 2009;42:1-8.
39.
PopeHGJrKeckPEJrMcElroySL. A placebo controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol. 1989;9:254-259.
40.
FichterMMLeiblKRiefW. Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry. 1991;24:1-7.
41.
WalshBTHadiganCMDevlinMJ. Long-term outcome of antidepressant treatment for bulimia nervosa. Am J Psychiatry. 1991;148:1206-1212.
42.
AgrasWSRossiterEMArnowB. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry. 1992;149:82-87.
43.
Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry. 1992;49:139-147.
44.
KennedySHGoldbloomDSRalevskiE. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. J Clin Psychopharmacol. 1993;13:415-422.
45.
AgrasWSRossiterEMArnowB. One-year follow-up of psychosocial and pharmacologic treatments for bulimia nervosa. J Clin Psychiatry. 1994;55:179-183.
46.
GoldsteinDJWilsonMGThompsonVL. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry. 1995;166:660-666.
47.
KanervaRRissanenASarnaS. Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa. Nord J Psychiatry. 1994;49:237-242.
48.
FichterMMKrugerRRiefW. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol. 1996;16:9-18.
49.
BeaumontPJRussellJDTouyzSW. Intensive nutritional counseling in bulimia nervosa: a role for supplementation with fluoxetine?Aust N Z J Psychiatry. 1997;31:514-524.
50.
FichterMMLeiblCKrugerR. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry. 1997;30:85-92.
51.
GoldbloomDSOlmstedMDavisR. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav Res Ther. 1997;35:803-811.
52.
WalshBTWilsonGTLoebKL. Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry. 1997;154:523-531.
53.
GoldsteinDJWilsonMGAscroftRC. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord. 1999;25:19-27.
54.
WilsonGTLoebKLWalshBT. Psychological versus pharmacological treatments of bulimia nervosa: predictors and processes of change. J Consult Clin Psychol. 1999;67:451-459.
55.
FarisPLKimSWMellerWH. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomized, double blind trial. Lancet. 2000;355:792-797.
56.
CarrubaMOCuzzolaroMRivaL. Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int J Clin Psychopharmacol. 2001;16:27-32.
57.
MitchellJEFletcherLHansonK. The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol. 2001;21:298-304.
58.
MitchellJEHalmiKWilsonGT. A randomized secondary treatment study of women with bulimia nervosa who fail to respond to CBT. Int J Eat Disord. 2002;32:271-281.
59.
RomanoSJHalmiKASarkarNP. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry. 2002;159:96-102.
60.
HoopesSPReimherrFWHedgesDW. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry. 2003;64:1335-1341.
61.
HedgesDWReimherrFWHoopesSP. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64:1449-1454.
62.
WalshBTFairburnCGMickleyD. Treatment of bulimia nervosa in a primary care setting. Am J Psychiatry. 2004;161:556-561.
63.
SundbladCLandenMErikssonT. Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J Clin Psychopharmacol. 2005;25:85-88.
64.
AgrasWSTelchCFArnowB. Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder: an additive design. Behav Ther. 1994;25:225-238.
65.
StunkardABerkowitzRTanrikutC. D-fenfluramine treatment of binge eating disorder. Am J Psychiatry. 1996;153:1455-1459.
66.
HudsonJIMcElroySLRaymondNC. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry. 1998;155:1756-1762.
67.
Laederach-HofmannKGrafCHorberF. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord. 1999;26:231-244.
68.
McElroySLCasutoLSNelsonEB. Placebo controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157:1004-1006.
69.
RiccaVMannucciEMezzaniB. Fluoxetine and fluvoxamine combined with individual cognitive behavior therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom. 2001;70:298-306.
70.
ArnoldLMMcElroySLHudsonJI. A placebo controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry. 2002;63:1028-1033.
71.
AppolinarioJCBacaltchukJSichieriR. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003;60:1109-1116.
72.
McElroySLHudsonJIMalhotraS. Citalopram in the treatment of binge-eating disorder: a placebo controlled trial. J Clin Psychiatry. 2003;64:807-813.
73.
McElroySLArnoldLMShapiraNA. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo controlled trial. Am J Psychiatry. 2003;160:255-261.
74.
PearlsteinTSpurellEHohlsteinLA. A double blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Women Ment Health. 2003;6:147-151.
75.
GriloCMMashebRMWilsonGT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57:301-309.
76.
GriloCMMashebRMSalantSL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005;57:1193-1201.
